Transcatheter Cardiovascular Therapeutics (TCT)

The Transcatheter Cardiovascular Therapeutics (TCT) conference is the Cardiovascular Research Foundation's (CRF) annual scientific symposium and the largest conference focused on interventional cardiovascular medicine. TCT includes seminars on all areas of intervention cardiology, structural heart, vascular in interventions, peripheral artery disease, and other procedures in the cath lab.

Cardiologist shares his long journey from Libya to United States
Abdel Almanfi, MD, went through years of training in Libya, but then he had to start over once he landed in the United States.
Cardiologists share historic research that led to FDA’s long-awaited approval of coronary DCB
When Boston Scientific’s coronary DCB gained approval in the United States, it was a moment the country's cardiologists had been looking forward to for years. The cardiologists who researched the device have now detailed their findings, highlighting the "unmet need" this technology is addressing.
Why financial literacy is so important for structural heart program directors
Carrie Redick, an ICU nurse for nearly 20 years, said understanding more about financial data improved her ability to acquire funding and other resources for her program when necessary.
Data registries have been a huge success for U.S. structural heart programs
ACC/STS National Cardiovascular Data Registry metrics reporting for TAVR is important for marketing and care quality, explains Patricia Keegan, NP, with the Emory Heart and Vascular Center.
CroíValve kicks off early feasibility study for new TR device, names cardiologist Martin Leon to advisory board
The company hopes to enroll 15 patients to monitor the safety and effectiveness of its new-look transcatheter device for severe tricuspid regurgitation.

The Cephea transcatheter mitral valve in development has been acquired by Medtronic.

Abbott acquires another TMVR device through purchase of Cephea

Abbott plans to acquire Cephea Valve Technologies, a company developing a transcatheter mitral valve replacement (TMVR) device, the Chicago-area healthcare giant announced Jan. 16.

January 16, 2019

The Abbott MitraClip is the primary structural heart device used in transcatheter edge-to-edge repairs (TEER) of the mitral valve leaflets. The results of the COAPT trial dropped like a thunderclap Sunday at the Transcatheter Cardiovascular Therapeutics (TCT) annual meeting, with several cardiologists predicting the MitraClip device will have a swift and lasting impact on the treatment of heart failure patients.

After COAPT: Getting MitraClip Right in the Real World

Will operators be able to replicate COAPT’s restraint and its outcomes?

January 7, 2019

TCT.18: COAPT draws superlatives, raises questions about replicating MitraClip’s benefits

Compared to heart failure patients with severe secondary mitral regurgitation who were treated with guideline-directed medical therapy alone, those randomized to a MitraClip procedure plus optimal medical therapy demonstrated relative reductions of 47 percent for heart failure hospitalizations and 38 percent for mortality at two years of follow-up.

September 23, 2018

Transcatheter Cardiovascular Therapeutics (TCT)

Cardiologist shares his long journey from Libya to United States

Cardiologists share historic research that led to FDA’s long-awaited approval of coronary DCB

Why financial literacy is so important for structural heart program directors

Data registries have been a huge success for U.S. structural heart programs

CroíValve kicks off early feasibility study for new TR device, names cardiologist Martin Leon to advisory board